What Trobalt contains
The active substance is retigabine. Each tablet contains 50 mg, 100 mg, 200 mg, 300 mg or 400 mg retigabine.
The other ingredients are: croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, macrogol 3350, titanium dioxide (E171) and talc (E553b). The 50 mg and 400 mg tablets also contain indigo carmine aluminium lake (E132) and carmine (E120).
The 100 mg and 300 mg tablets also contain indigo carmine aluminium lake (E132) and iron oxide yellow (E172).
The 200 mg tablets also contain iron oxide yellow (E172).
What Trobalt looks like and contents of the pack
Trobalt 50 mg tablets are purple, round and marked ?RTG 50? on one side. Each pack contains blisters of 21, 84 or 168 film-coated tablets.
Trobalt 100 mg tablets are green, round and marked ?RTG 100? on one side. Each pack contains blisters of 21, 84 or 168 film-coated tablets.
Trobalt 200 mg tablets are yellow, oblong and marked ?RTG-200? on one side. Each pack contains blisters of 84 or 2 x 84 film-coated tablets.
Trobalt 300 mg tablets are green, oblong and marked ?RTG-300? on one side. Each pack contains blisters of 84 or 2 x 84 film-coated tablets.
Trobalt 400 mg tablets are purple, oblong and marked ?RTG-400? on one side. Each pack contains blisters of 84 or 2 x 84 film-coated tablets.
A Treatment Initiation Pack is also available for use during the first two weeks of treatment when the dose is being slowly increased. The Treatment Initiation Pack contains 63 tablets, in 2 blisters. The blister for Week 1 of treatment contains 21 x 100 mg tablets. The blister for Week 2 contains 21 x 50 mg tablets and 21 x 100 mg tablets.
Not all pack sizes may be available in your country.
Marketing Authorisation Holder
Glaxo Group Limited, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom.
Manufacturer
Treatment Initiation Pack ? Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom.
All other packs ? Glaxo Wellcome, S.A, Avda. Extremadura 3, 09400 Aranda De Duero, Burgos, Spain.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien GlaxoSmithKline s.a.n.v. TélTel 32 02 656 21 11 LuxembourgLuxemburg GlaxoSmithKline s.a.n.v. BelgiqueBelgien TélTel 32 02 656 21 11
Te. 359 2 953 10 34 Magyarország GlaxoSmithKline Kft. Tel. 36 1 225 5300
Malta GlaxoSmithKline Malta Tel 356 21 238131 eská republika GlaxoSmithKline s.r.o. Tel 420 222 001 111 gsk.czmailgsk.com
Danmark GlaxoSmithKline Pharma AS Tlf 45 36 35 91 00 dk-infogsk.com Nederland GlaxoSmithKline BV Tel 31 030 6938100 nlinfogsk.com
Deutschland GlaxoSmithKline GmbH Co. KG Tel. 49 089 36044 8701 produkt.infogsk.com Norge GlaxoSmithKline AS Tlf 47 22 70 20 00 firmapostgsk.no
Eesti GlaxoSmithKline Eesti OÜ Tel 372 6676 900 estoniagsk.com Österreich GlaxoSmithKline Pharma GmbH Tel 43 01 97075 0 at.infogsk.com
Polska
GlaxoSmithKline A.E.B.E. 30 210 68 82 100 GSK Commercial Sp. z o.o. Tel. 48 022 576 9000
España GlaxoSmithKline, S.A. Tel 34 902 202 700 es-cigsk.com Portugal GlaxoSmithKline Produtos Farmacêuticos, Lda. Tel 351 21 412 95 00 FI.PTgsk.com
România GlaxoSmithKline GSK S.R.L. Tel 4021 3028 208 France Laboratoire GlaxoSmithKline Tél. 33 01 39 17 84 44 diamgsk.com
Ireland GlaxoSmithKline Ireland Limited Tel 353 01 4955000 Slovenija GlaxoSmithKline d.o.o. Tel 386 01 280 25 00 medical.x.sigsk.com
Ísland GlaxoSmithKline ehf. Sími 354 530 3700 Slovenská republika GlaxoSmithKline Slovakia s. r. o. Tel 421 02 48 26 11 11 recepcia.skgsk.com
Italia GlaxoSmithKline S.p.A. Tel 39 045 9218 111 SuomiFinland GlaxoSmithKline Oy PuhTel 358 010 30 30 30 Finland.tuoteinfogsk.com
GlaxoSmithKline Cyprus Ltd 357 22 39 70 00 Sverige GlaxoSmithKline AB Tel 46 08 638 93 00 info.produktgsk.com
Latvija GlaxoSmithKline Latvia SIA Tel 371 67312687 lv-epastsgsk.com United Kingdom GlaxoSmithKline UK Tel 44 0800 221441 customercontactukgsk.com
Lietuva
GlaxoSmithKline Lietuva UAB
Tel: + 370 5 264 90 00
info.lt@gsk.com
This leaflet was last approved in